Bo Chen
Relypsa Inc., USA
Title: The development of nonabsorbed potassium binding polymer microparticles (patiromer) for the treatment of hyperkalemia
Biography
Biography: Bo Chen
Abstract
Hyperkalemia is a potentially life-threatening condition, and patients who have chronic kidney disease, who are diabetic, or who are taking renin–angiotensin–aldosterone system inhibitors are at increased risk. Therapeutic options for hyperkalemia tend to have limited effectiveness and can be associated with serious side effects. There is no new therapeutics for more than 50 years. Patiromer (USAN, trade name Veltassa) is a novel, spherical, nonabsorbed polymer designed to bind and remove potassium, primarily in the colon, thereby decreasing serum potassium in patients with hyperkalemia. The development process and the results of prelinical studies and early phase clinical study are reported here. Overall, patiromer is a high-capacity potassium binder, and the chemical and physical characteristics of patiromer can lead to good clinical efficacy, tolerability, and patient acceptance. It has been approved in 2015 by FDA used for the treatment of hyperkalemia.